Status:
RECRUITING
Effect of Captopril on GLS in Duchenne Myodystrophy
Lead Sponsor:
Ain Shams University
Conditions:
Effect of Drug
Eligibility:
MALE
6+ years
Phase:
EARLY_PHASE1
Brief Summary
To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DM...
Detailed Description
ACEI slowing down the onset and the progression of dystrophinopathic cardiomyopathy. To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular function...
Eligibility Criteria
Inclusion
- Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \< -18% with minimum age of 6 years old.
Exclusion
- Any patient who refuses to sign an informed consent.
- Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
- Reduced ejection fraction below 50%.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06485661
Start Date
January 1 2024
End Date
September 30 2024
Last Update
July 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams university
Cairo, Egypt